MA46997B1 - Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique - Google Patents
Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmiqueInfo
- Publication number
- MA46997B1 MA46997B1 MA46997A MA46997A MA46997B1 MA 46997 B1 MA46997 B1 MA 46997B1 MA 46997 A MA46997 A MA 46997A MA 46997 A MA46997 A MA 46997A MA 46997 B1 MA46997 B1 MA 46997B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- active pharmaceutical
- pharmaceutical substance
- administration
- cyclodextrin complexes
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des compositions ophtalmiques contenant des complexes solides de substance pharmaceutique active et de cyclodextrine, leur méthode de préparation et leurs utilisations. Les compositions peuvent comprendre un complexe médicament à principe actif/cyclodextrine sensiblement dissout dans un vecteur aqueux de gouttes ophtalmiques. La composition ophtalmique se présente globalement sous la forme d'une microsuspension comprenant un complexe de principes actifs ayant un diamètre inférieur à environ 100 µm.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662427737P | 2016-11-29 | 2016-11-29 | |
PCT/IB2017/001659 WO2018100434A1 (fr) | 2016-11-29 | 2017-11-29 | Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique |
Publications (2)
Publication Number | Publication Date |
---|---|
MA46997A MA46997A (fr) | 2019-10-09 |
MA46997B1 true MA46997B1 (fr) | 2022-01-31 |
Family
ID=61656066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA46997A MA46997B1 (fr) | 2016-11-29 | 2017-11-29 | Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique |
Country Status (30)
Country | Link |
---|---|
US (6) | US20190343846A1 (fr) |
EP (2) | EP3548091B1 (fr) |
JP (2) | JP7138103B2 (fr) |
KR (3) | KR102525438B1 (fr) |
CN (2) | CN110177576B (fr) |
AR (2) | AR110269A1 (fr) |
AU (1) | AU2017369971B2 (fr) |
CA (1) | CA3045226A1 (fr) |
CL (1) | CL2019001447A1 (fr) |
CO (1) | CO2019005729A2 (fr) |
CY (1) | CY1124917T1 (fr) |
DK (1) | DK3548091T3 (fr) |
EA (1) | EA201991299A1 (fr) |
ES (1) | ES2903383T3 (fr) |
HR (1) | HRP20220046T1 (fr) |
HU (1) | HUE057221T2 (fr) |
IL (2) | IL310360A (fr) |
LT (1) | LT3548091T (fr) |
MA (1) | MA46997B1 (fr) |
MD (1) | MD3548091T2 (fr) |
MX (1) | MX2019006221A (fr) |
PH (1) | PH12019550088A1 (fr) |
PL (1) | PL3548091T3 (fr) |
PT (1) | PT3548091T (fr) |
RS (1) | RS62845B1 (fr) |
SI (1) | SI3548091T1 (fr) |
TW (2) | TWI773706B (fr) |
UA (1) | UA124774C2 (fr) |
WO (1) | WO2018100434A1 (fr) |
ZA (1) | ZA201903307B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2903383T3 (es) * | 2016-11-29 | 2022-04-01 | Oculis SA | Preparación de complejos sólidos de ciclodextrina para la administración de un principio farmacéutico activo oftálmico |
IT201900000561A1 (it) * | 2019-01-14 | 2020-07-14 | Medivis S R L | Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac |
CN110051859B (zh) * | 2019-06-06 | 2020-06-12 | 鲁南制药集团股份有限公司 | 一种阿昔替尼环糊精包合物 |
JP2022538659A (ja) * | 2019-07-01 | 2022-09-05 | オキュリス エスエー | 薬剤を含む水性組成物のpHを安定化させるための方法 |
TWI756547B (zh) * | 2019-07-15 | 2022-03-01 | 高雄榮民總醫院 | 奈米眼藥水及其製造方法 |
EP4171507A1 (fr) * | 2020-06-30 | 2023-05-03 | Oculis SA | Préparation de complexes de cyclodextrine solides pour l'administration de substance pharmaceutique active ophtalmique |
CN111728953B (zh) * | 2020-07-29 | 2023-08-08 | 中国科学院上海药物研究所 | 一种托法替布或其盐的缓释制剂及其制备方法 |
JP2024504980A (ja) * | 2021-01-21 | 2024-02-02 | テジュン ファーマシューティカル カンパニー リミテッド | 点眼組成物 |
US11998562B2 (en) * | 2021-01-25 | 2024-06-04 | University Of South Florida | Ophthalmological formulations for the prevention of a coronavirus infection |
WO2023132947A1 (fr) * | 2022-01-05 | 2023-07-13 | The Regents Of The University Of California | Complexes de closo-dodécaiododécaborate et leurs procédés d'utilisation |
AU2023214622A1 (en) | 2022-02-02 | 2024-08-08 | Oculis Operations Sarl | Multidose ophthalmic compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
EP0938896A1 (fr) * | 1998-01-15 | 1999-09-01 | Novartis AG | Compositions pharmaceutiques autoclavables contenant des agents de chelation |
US20020198174A1 (en) * | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
MXPA03004241A (es) * | 2000-11-15 | 2004-12-03 | Chandavarkar Mohan A | Preparaciones farmaceuticas que comprenden corticosteroides y agentes antiinfecciosos. |
WO2004069280A1 (fr) | 2003-02-06 | 2004-08-19 | Cipla Ltd | Complexes d'inclusion pharmaceutiques contenant un steroide et un agent antibacterien facultatif |
BRPI0407583A (pt) * | 2003-02-21 | 2006-02-14 | Sun Pharmaceutical Ind Ltd | solução oftálmica lìmpida e estável |
US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
US20140163080A1 (en) * | 2011-02-03 | 2014-06-12 | Gnt, Llc | Compositions and Methods for Treatment of Glaucoma |
JP6410264B2 (ja) * | 2012-05-08 | 2018-10-24 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | ペプチドプロテアソーム阻害剤を調合するためのシクロデキストリン錯体形成法 |
EP2887923B1 (fr) * | 2012-08-24 | 2023-04-05 | Sun Pharmaceutical Industries Limited | Formulation ophtalmique d'acide gras ou lipidique de polyoxyle, et traitement de pathologies oculaires |
ES2903383T3 (es) * | 2016-11-29 | 2022-04-01 | Oculis SA | Preparación de complejos sólidos de ciclodextrina para la administración de un principio farmacéutico activo oftálmico |
-
2017
- 2017-11-29 ES ES17851871T patent/ES2903383T3/es active Active
- 2017-11-29 US US16/465,138 patent/US20190343846A1/en not_active Abandoned
- 2017-11-29 SI SI201731027T patent/SI3548091T1/sl unknown
- 2017-11-29 KR KR1020197018914A patent/KR102525438B1/ko active IP Right Grant
- 2017-11-29 EA EA201991299A patent/EA201991299A1/ru unknown
- 2017-11-29 US US15/826,247 patent/US11135311B2/en active Active
- 2017-11-29 IL IL310360A patent/IL310360A/en unknown
- 2017-11-29 AR ARP170103327A patent/AR110269A1/es unknown
- 2017-11-29 RS RS20220012A patent/RS62845B1/sr unknown
- 2017-11-29 KR KR1020237004598A patent/KR20230025939A/ko not_active Application Discontinuation
- 2017-11-29 EP EP17851871.8A patent/EP3548091B1/fr active Active
- 2017-11-29 CN CN201780073668.0A patent/CN110177576B/zh active Active
- 2017-11-29 WO PCT/IB2017/001659 patent/WO2018100434A1/fr unknown
- 2017-11-29 MA MA46997A patent/MA46997B1/fr unknown
- 2017-11-29 CA CA3045226A patent/CA3045226A1/fr active Pending
- 2017-11-29 LT LTEPPCT/IB2017/001659T patent/LT3548091T/lt unknown
- 2017-11-29 UA UAA201907103A patent/UA124774C2/uk unknown
- 2017-11-29 PT PT178518718T patent/PT3548091T/pt unknown
- 2017-11-29 DK DK17851871.8T patent/DK3548091T3/da active
- 2017-11-29 AR ARP170103328A patent/AR110270A1/es unknown
- 2017-11-29 JP JP2019528740A patent/JP7138103B2/ja active Active
- 2017-11-29 EP EP21209378.5A patent/EP4194011A1/fr active Pending
- 2017-11-29 MX MX2019006221A patent/MX2019006221A/es unknown
- 2017-11-29 HU HUE17851871A patent/HUE057221T2/hu unknown
- 2017-11-29 TW TW106141577A patent/TWI773706B/zh active
- 2017-11-29 MD MDE20191148T patent/MD3548091T2/ro unknown
- 2017-11-29 KR KR1020247008223A patent/KR20240036731A/ko active Search and Examination
- 2017-11-29 IL IL266964A patent/IL266964B2/en unknown
- 2017-11-29 CN CN202311057733.4A patent/CN117018220A/zh active Pending
- 2017-11-29 TW TW106141572A patent/TWI810167B/zh active
- 2017-11-29 AU AU2017369971A patent/AU2017369971B2/en active Active
- 2017-11-29 PL PL17851871T patent/PL3548091T3/pl unknown
- 2017-11-29 HR HRP20220046TT patent/HRP20220046T1/hr unknown
-
2019
- 2019-05-24 ZA ZA2019/03307A patent/ZA201903307B/en unknown
- 2019-05-27 PH PH12019550088A patent/PH12019550088A1/en unknown
- 2019-05-28 CL CL2019001447A patent/CL2019001447A1/es unknown
- 2019-05-31 CO CONC2019/0005729A patent/CO2019005729A2/es unknown
-
2021
- 2021-09-28 US US17/487,354 patent/US11491240B2/en active Active
-
2022
- 2022-01-25 CY CY20221100060T patent/CY1124917T1/el unknown
- 2022-09-05 JP JP2022140610A patent/JP7455917B2/ja active Active
- 2022-09-28 US US17/955,064 patent/US20230037486A1/en not_active Abandoned
- 2022-10-26 US US17/973,749 patent/US20230042785A1/en active Pending
-
2023
- 2023-11-22 US US18/517,529 patent/US20240091377A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46997B1 (fr) | Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique | |
Chiodo et al. | Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs | |
Kovarova et al. | Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission | |
AU2019219767A1 (en) | Treatments for resistant acne | |
de Faria et al. | An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages | |
Kumar et al. | Triple drug combination of zidovudine, efavirenz and lamivudine loaded lactoferrin nanoparticles: an effective nano first-line regimen for HIV therapy | |
MA50240B1 (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MY166045A (en) | Abeta antibody formulation | |
WO2007027941A3 (fr) | Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue | |
MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
EA201891977A1 (ru) | Стабильная парентеральная лекарственная форма нимодипина | |
JP2011516613A5 (fr) | ||
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
EA201890367A1 (ru) | Композиции и способы для лиофильных форм наночастиц | |
MA35411B1 (fr) | Nouvelle composition thérapeutique contenant de l'apomorphine comme principe actif | |
JP2016539921A5 (fr) | ||
RU2017146716A (ru) | Способ образования наночастиц циклоспорина а/ циклодекстрина | |
MA33676B1 (fr) | Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée | |
Jain et al. | Parasite impairment by targeting Plasmodium-infected RBCs using glyceryl-dilaurate nanostructured lipid carriers | |
AU2016338637A1 (en) | Combination antibacterial composition and short-course antibacterial regimen | |
Omolo et al. | Formulation of pH responsive multilamellar vesicles for targeted delivery of hydrophilic antibiotics | |
EP4233850A3 (fr) | Formulations de capsules | |
MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 |